View Financial HealthShuttle Pharmaceuticals Holdings 配当と自社株買い配当金 基準チェック /06Shuttle Pharmaceuticals Holdings配当金を支払った記録がありません。主要情報n/a配当利回り-304.4%バイバック利回り総株主利回り-304.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesShuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $11 million in fundingMay 01Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 21, 2026Apr 13Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3.500001 million.Feb 11New major risk - Share price stability Dec 16Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes, Effective November 21, 2025Nov 29Shuttle Pharmaceuticals Regains Nasdaq ComplianceNov 18Less than half of directors are independent Sep 24Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4.249998 million in funding from Lytham Partners, LLCJun 25Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $4.251157 million in fundingJun 21New major risk - Share price stability Jun 12Shuttle Pharmaceuticals Holdings, Inc. Appoints George Scorsis as Chairman of the Board of DirectorsJun 05New major risk - Financial position May 10Shuttle Pharmaceuticals Holdings, Inc. Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApr 11Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, May 09, 2025Mar 20Shuttle Pharmaceuticals Provides Update Regarding Minimum Equity Requirement of NasdaqMar 14Shuttle Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5.732174 million.Mar 13Shuttle Pharmaceuticals Holdings, Inc. Appoints Christopher Cooper as Interim Co-CEOMar 12Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.Feb 13New major risk - Shareholder dilution Nov 29Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First PatientNov 26New major risk - Negative shareholders equity Nov 15Shuttle Pharmaceuticals Holdings, Inc. Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaOct 29+ 1 more updateShuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in fundingOct 18Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.Sep 20Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaSep 16Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity RequirementSep 14Shuttle Pharmaceuticals Provides Regains Compliance with Nasdaq Listing Rule 5250(c)Sep 05Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementAug 29Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)Aug 28Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaAug 15Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filingAug 14Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303Jul 20Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer ChangesJun 18Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Jul 31, 2024Jun 13New major risk - Financial position May 15New major risk - Financial position Mar 24New minor risk - Share price stability Jan 22Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaJan 08Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaDec 11New minor risk - Share price stability Oct 25Shuttle Pharmaceuticals Holdings, Inc., Annual General Meeting, Dec 18, 2023Oct 22Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaSep 26Shuttle Pharmaceuticals Holdings, Inc. Expands Patent Coverage on HDAC Inhibitor PlatformSep 12Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementSep 08New major risk - Financial position Aug 16Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing RulesMay 29Shuttle Pharmaceuticals Holdings, Inc. announced delayed 10-Q filingMay 16Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLCJan 13Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for CancerJan 12Insufficient new directors Nov 16Shuttle Pharmaceuticals Holdings, Inc. Appoints Bette Jacobs to Its Board of DirectorsNov 02Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer TreatmentSep 16Shuttle Pharma awarded new patents for its radiation sensitizing technology platform Sep 15Shuttle Pharmaceuticals Holdings, Inc. has completed an IPO in the amount of $9.96034 million.Sep 01決済の安定と成長配当データの取得安定した配当: SHPHの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SHPHの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Shuttle Pharmaceuticals Holdings 配当利回り対市場SHPH 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SHPH)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (SHPH) (最長3年)n/a注目すべき配当: SHPHは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SHPHは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SHPHの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SHPHが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 02:29終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shuttle Pharmaceuticals Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $11 million in fundingMay 01
Shuttle Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $3.500001 million.Feb 11
Shuttle Pharmaceuticals Holdings, Inc. Announces Chief Financial Officer Changes, Effective November 21, 2025Nov 29
Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4.249998 million in funding from Lytham Partners, LLCJun 25
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $4.251157 million in fundingJun 21
Shuttle Pharmaceuticals Holdings, Inc. Appoints George Scorsis as Chairman of the Board of DirectorsJun 05
Shuttle Pharmaceuticals Holdings, Inc. Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate CancerApr 11
Shuttle Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5.732174 million.Mar 13
Shuttle Pharmaceuticals Holdings, Inc. Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First PatientNov 26
Shuttle Pharmaceuticals Holdings, Inc. Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaOct 29+ 1 more update
Shuttle Pharmaceuticals Holdings, Inc. announced that it expects to receive $1.3 million in fundingOct 18
Shuttle Pharmaceuticals Holdings, Inc. Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with GlioblastomaSep 16
Shuttle Pharmaceuticals Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity RequirementSep 14
Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaAug 15
Shuttle Pharmaceuticals Holdings, Inc. Announces Publication of A Manuscript Reporting on the Ability of One of the Company’s HDAC Inhibitor Pre-Clinical Assets, SP-1-303Jul 20
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with GlioblastomaJan 08
Shuttle Pharmaceuticals Holdings, Inc. Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaDec 11
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with GlioblastomaSep 26
Shuttle Pharmaceuticals Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price RequirementSep 08
Shuttle Pharmaceuticals Holdings Files Form 10-Q with the Securities and Exchange Commission and Regains Compliance with the Nasdaq Listing RulesMay 29
Shuttle Pharmaceuticals Holdings, Inc. announced that it has received $4 million in funding from Ayrton Capital LLCJan 13
Shuttle Pharmaceuticals Holdings, Inc. Announces the Publication of Manuscript Discussing Immune Responses Taking Place in Patients After Radiation Therapy for CancerJan 12
Shuttle Pharmaceuticals Holdings, Inc. Receives New HDAC Inhibitor Patents for Cancer TreatmentSep 16